Results 151 to 160 of about 31,601 (273)

Out of the Straitjacket. [PDF]

, 2018
Weinstein, Michael
core   +2 more sources

Diagnostic and prognostic value of fecal, serum and endoscopic markers in inflammatory bowel disease and colorectal cancer [PDF]

, 2018
Background. The most important goals of the recent therapies of inflammatory bowel disease (IBD) are to induce and maintain clinical remission and mucosal healing (MH), which can be achieved with anti-TNF-α biological therapy.
Rutka Mariann
core  

Is Asia Ready for Biosimilars? a Review of the Regulatory Landscape for Biosimilars? [PDF]

, 2018
S Duttagupta, S Park, D Akandwanaho, JJ Jeong, Hannah Feldman   +4 more
openalex   +1 more source

Severe Delayed Hypersensitivity Reaction at Guselkumab Injection Site

Contact Dermatitis, Volume 94, Issue 1, Page 89-91, January 2026.
Salomé Allichon, Julie Litovsky, Michèle Sanchez, Céline Girard, Guillaume Granier, Luc Durand, Maxime Henrion, Christelle Philibert, Cosette Le Souder, Nadia Raison‐Peyron   +9 more
wiley   +1 more source

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

Aging Medicine
Objective The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis.
Nitin Kapoor, Thomas Paul, Rajeshwar Nath Srivastava, Saurabh Singh, Sunil Maheshwari, Vishal Patil, Awadhesh Kumar Yadav, Girish Bhatia, Sushil H. Mankar, Joe Joseph Cherian, Surabhi Maheshwari, Sudeepti Srivastava, Dattatray Pawar, Roshan Pawar, Amol Aiwale, Amitrajit Pal, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma   +18 more
doaj   +1 more source

Biosimilars: Key regulatory considerations and similarity assessment tools [PDF]

, 2017
Carol F. Kirchhoff, Xiao‐Zhuo Michelle Wang, Hugh D. Conlon, Scott Anderson, Anne Ryan, Arindam Bose   +5 more
openalex   +1 more source

Biosimilar insulin: the current landscape [PDF]

, 2017
Andrea Llano, Miles Fisher, Gerry McKay
openalex   +1 more source

Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities [PDF]

, 2021
Hasumati Rahalkar, Alan Sheppard, Gustavo Mendes Lima Santos, Chitralekha Nag Dasgupta, Sonia Mayra Pérez‐Tapia, Carlos A. López‐Morales, Sam Salek   +6 more
openalex   +1 more source

Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial [PDF]

, 2022
Ahmadreza Jamshidi, Mahdi Vojdanian, Mohsen Soroush, M. Akbarian, Mehrdad Aghaei, Asghar Hajiabbasi, Zahra Mirfeizi, Alireza Khabbazi, Gholam Hossein Alishiri, Anousheh Haghighi, Ahmad Salimzadeh, Hadi Karimzadeh, Fatemeh Shirani, Mohammad Reza Hatef Fard, Mohammad Ali Nazarinia, Soosan Soroosh, Nassim Anjidani, Farhad Gharibdoost   +17 more
openalex   +1 more source

Biosimilar medicines and cost-effectiveness

ClinicoEconomics and Outcomes Research, 2011
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj